Targeting the Japanese Medical AI Market with Full-Lineup of AITRICS-VC (VitalCare) and V.Doc Pro

AITRICS (CEO Kwang Joon Kim), a company specializing in artificial intelligence(AI) technology announced on the 29 that it will participate in Medical Japan Tokyo 2025, a premier Japanese medical industry exhibition, taking place from October 1 to 3.

Medical Japan is a leading professional exhibition showcasing the latest medical technologies and products to the global market, held annually in Osaka and Tokyo. At this year’s event, AITRICS will focus on AI-driven proactive care and workflow innovation across the entire medical process, from hospitals to clinics, highlighting its flagship products: AITRICS-VC (VitalCare) and V.Doc Pro.

VitalCare is a medical AI solution that analyzes electronic medical record (EMR) data to predict early risks of sepsis, cardiac arrest, and mortality, supporting timely clinical decision-making by healthcare professionals. V.Doc Pro, powered by AITRICS’ proprietary healthcare-specialized large language model (LLM), serves as an AI co-pilot for medical staff, allowing them to focus on patient care by streamlining tasks from pre-consultation preparation and conversation recording to post-consultation follow-up.

Through these two solutions, AITRICS aims to enable proactive patient monitoring and response while simultaneously improving efficiency in clinical settings. Japan, facing an aging population and healthcare workforce shortages, has a high demand for AI-based clinical decision support and hospital operational efficiency solutions, making this exhibition an ideal opportunity to expand local partnerships.

CEO Kwang Joon Kim stated, “Japan is actively adopting medical AI, and its market is growing rapidly. Through our participation in Medical Japan, we aim to showcase the proven capabilities of AITRICS’ AI technology and provide an environment where healthcare professionals can stay one step ahead in patient care.” He added, “We will continue to drive operational innovation and enhance patient safety in clinical settings through AI, not only in Japan but also in global markets.”